AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
indocyanine green 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 3300 | 3599-32-4 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A tricarbocyanine dye that is used diagnostically in liver function tests and to determine blood volume and cardiac output.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Hosey CM, Chan R, Benet LZ |
| Vd (Volume of distribution) | 0.04 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 6.80 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.05 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 0.07 hours | Lombardo F, Berellini G, Obach RS |
| S (Water solubility) | 1 mg/mL | Bocci G, Oprea TI, Benet LZ |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,ACVRL1,AKT1,AKT2,AKT3,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FGFR1,FLT3,GRK2,GRK3,GSK3B,IGF1R,IKBKB,INSR,ITK,JAK1,JAK2,JAK3,KDR,KIT,MAP2K6,MAP3K1,MAP3K14,MAP3K21,MAP3K7,MAP4K1,MAPK1,MAPK10,MAPK12,MAPK14,MAPK7,MAPK8,MAPK9,MAPKAPK2,MAPKAPK5,MARK4,MET,MTOR,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIK3CD,PIM1,PIM2,PLK1,PRKCD,PRKDC,SIK2,SIK3,STK10,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ULK2,ZAP70 | 78 | |||
| kinase-selectivity-class | AXL,BRAF,CAMK2D,CDK4,CDK9,DDR1,EIF2AK3,EPHB4,ERBB2,GRK2,INSR,JAK2,MAP2K6,MAPK1,MAPK12,MAPK7,PIK3CD,PRKDC,SIK2,STK10,STK33,SYK,TEK,TTK,ZAP70 | 25 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Feb. 9, 1959 | FDA | AKORN | |
| July 2, 2018 | PMDA | Daiichi Sankyo Company, Limited |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Haemangioma congenital | 95.16 | 75.08 | 11 | 110 | 545 | 90627781 |
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | V04CX01 | VARIOUS DIAGNOSTIC AGENTS OTHER DIAGNOSTIC AGENTS Other diagnostic agents |
| FDA MoA | N0000175533 | Dyes |
| FDA EPC | N0000175536 | Diagnostic Dye |
| MeSH PA | D004396 | Coloring Agents |
Related Drugs by ATC class:
V04CX Other diagnostic agents 9 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Evaluation of vascular and tissue blood flow | indication | 35202002 | |
| Sentinel lymph node mapping in breast cancer | indication | 274415007 | |
| Sentinel lymph node mapping in malignant melanoma | indication | 274415007 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 0.41 | acidic |
| pKa2 | 1.01 | acidic |
| pKa3 | 4.91 | Basic |
| pKa4 | 4.31 | Basic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 25MG/VIAL | SPY AGENT GREEN KIT | NOVADAQ TECH | N211580 | Nov. 21, 2018 | RX | POWDER | INTRAVENOUS, INTERSTITIAL | 8185176 | June 4, 2028 | VISUALIZATION OF VESSELS, BLOOD FLOW AND TISSUE PERFUSION OF VESSEL WITH ARTERIOVENOUS MALFORMATION IN VASCULAR, GASTROINTESTINAL, ORGAN TRANSPLANT, AND PLASTIC, MICRO- AND RECONSTRUCTIVE, INCLUDING MINIMALLY INVASIVE, SURGERY |
| 25MG/VIAL | SPY AGENT GREEN KIT | NOVADAQ TECH | N211580 | Nov. 21, 2018 | RX | POWDER | INTRAVENOUS, INTERSTITIAL | 8647605 | Feb. 11, 2029 | VISUALIZATION OF EXTRAHEPATIC BILIARY DUCT ATTACHED TO TRANSPLANTED ORGAN IN PATIENTS 12 YEARS AND OLDER |
| 25MG/VIAL | SPY AGENT GREEN KIT | NOVADAQ TECH | N211580 | Nov. 21, 2018 | RX | POWDER | INTRAVENOUS, INTERSTITIAL | 8647605 | Feb. 11, 2029 | VISUALIZATION OF VESSELS, BLOOD FLOW AND TISSUE PERFUSION OF TRANSPLANTED ORGAN OR ATTACHED VESSEL IN VASCULAR, GASTROINTESTINAL, ORGAN TRANSPLANT, AND PLASTIC, MICRO- AND RECONSTRUCTIVE, INCLUDING MINIMALLY INVASIVE, SURGERY |
| 25MG/VIAL | SPY AGENT GREEN KIT | NOVADAQ TECH | N211580 | Nov. 21, 2018 | RX | POWDER | INTRAVENOUS, INTERSTITIAL | 8406860 | April 9, 2029 | VISUALIZATION OF VESSELS, BLOOD FLOW AND TISSUE PERFUSION IN SURGICAL FLAPS IN VASCULAR, GASTROINTESTINAL, ORGAN TRANSPLANT, AND PLASTIC, MICRO- AND RECONSTRUCTIVE, INCLUDING MINIMALLY INVASIVE, SURGERY |
| 25MG/VIAL | SPY AGENT GREEN KIT | NOVADAQ TECH | N211580 | Nov. 21, 2018 | RX | POWDER | INTRAVENOUS, INTERSTITIAL | 10631746 | Aug. 4, 2035 | MEASURING TIME-VARYING CHANGE IN BLOOD IN A TISSUE VOLUME USING MODIFIED BEER-LAMBERT LAW IN VASCULAR, GASTROINTESTINAL, ORGAN TRANSPLANT, AND PLASTIC, MICRO- AND RECONSTRUCTIVE, INCLUDING MINIMALLY INVASIVE, SURGERY |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| 25MG/VIAL | SPY AGENT GREEN KIT | NOVADAQ TECH | N211580 | Nov. 21, 2018 | RX | POWDER | INTRAVENOUS, INTERSTITIAL | June 5, 2026 | FOR FLUORESCENCE IMAGING OF LYMPH NODES AND DELINEATION OF LYMPHATIC VESSELS DURING LYMPHATIC MAPPING IN ADULTS WITH BREAST CANCER FOR WHICH THIS PROCEDURE IS A COMPONENT OF INTRAOPERATIVEMANAGEMENT |
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| 4018103 | VUID |
| N0000146441 | NUI |
| D01342 | KEGG_DRUG |
| 4018103 | VANDF |
| C0021234 | UMLSCUI |
| CHEBI:31696 | CHEBI |
| CHEMBL1646 | ChEMBL_ID |
| D007208 | MESH_DESCRIPTOR_UI |
| DB16024 | DRUGBANK_ID |
| 4844 | IUPHAR_LIGAND_ID |
| IX6J1063HV | UNII |
| 5282412 | PUBCHEM_CID |
| 5775 | RXNORM |
| 162283 | MMSL |
| 4876 | MMSL |
| d04098 | MMSL |
| 001225 | NDDF |
| 384954007 | SNOMEDCT_US |
| 7292004 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Zyogreen | HUMAN PRESCRIPTION DRUG LABEL | 1 | 25021-841 | INJECTION, SOLUTION | 2.50 mg | INTRAVENOUS | NDA | 24 sections |
| Indocyanine green | HUMAN PRESCRIPTION DRUG LABEL | 1 | 49673-424 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 25 mg | INTRAVENOUS | ANDA | 19 sections |
| Indocyanine green | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66259-424 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 25 mg | INTRAVENOUS | ANDA | 20 sections |
| IC-Green | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66259-701 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 25 mg | INTRAVENOUS | NDA | 21 sections |
| IC-GREEN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69450-701 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 25 mg | INTRAVENOUS | NDA | 21 sections |
| Indocyanine green | HUMAN PRESCRIPTION DRUG LABEL | 1 | 75874-424 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 25 mg | INTRAVENOUS | ANDA | 19 sections |
| IC-Green | HUMAN PRESCRIPTION DRUG LABEL | 1 | 75874-701 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 25 mg | INTRAVENOUS | NDA | 21 sections |